SCB-2019

Abdera Therapeutics Expands Management Team and Board of Directors

Retrieved on: 
Tuesday, January 30, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Sanofi, Pfizer, Neoplasm, National Cancer Institute, Science, Law, Novartis, Gorilla, Carcinoma, DLL3, Genentech, National Institutes of Health, Food, Therapy, Acquisition, Rest, Bangladesh Technical Education Board, Hematology, Princeton University, Gilead Sciences, University, Cancer, Internal medicine, SCB-2019, Pharmaceutical industry

“We are thrilled to welcome Philippe and Eric to Abdera,” said Lori Lyons-Williams, president and chief executive officer.

Key Points: 
  • “We are thrilled to welcome Philippe and Eric to Abdera,” said Lori Lyons-Williams, president and chief executive officer.
  • I am excited to join the Abdera team and help build a differentiated pipeline.”
    Mr. Dobmeier is an executive and board member with more than 20 years of experience in the biotechnology industry.
  • He currently serves on the boards of Structure Therapeutics and Atara Therapeutics.
  • “I look forward to working with the rest of the board and leadership team as Abdera prepares to transition into a clinical-stage company and enter its next phase of growth.”

Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer

Retrieved on: 
Friday, June 16, 2023
Vaccine, Clover, GMP, Good, University, Doctor of Philosophy, CMC, SCB-2019, Messenger, HKEX, Patient, Good manufacturing practice, Control, Microbiology, University of Manitoba, Pharmaceutical industry, Fine chemical, Medical device, Mount Everest, Chemistry

SHANGHAI, June 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on development, manufacturing and commercialization of innovative medicines and vaccines, today announced that Dr. Mike Berry has been appointed Chief Technology Officer, effective immediately.

Key Points: 
  • SHANGHAI, June 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on development, manufacturing and commercialization of innovative medicines and vaccines, today announced that Dr. Mike Berry has been appointed Chief Technology Officer, effective immediately.
  • As the Chief Technology Officer, Dr. Berry will be responsible for all CMC activities at Everest while being in charge of the operations and management of the Company's manufacturing facility in Jiashan, Zhejiang.
  • "Dr. Berry brings to Everest strong expertise and extensive experience in CMC and manufacturing that will help solidify our full industrial value chain," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.
  • Prior to this appointment, Dr. Berry was most recently Chief Technical Operations Officer for global operations at Clover Biopharmaceuticals, Ltd. (Clover) responsible for Clover's global drug substance and drug product development and manufacturing.

Clover Announces Corporate Updates and Full Year 2022 Financial Results

Retrieved on: 
Wednesday, March 29, 2023
EUA, Vaccine, GMP, SCB-2019, Cold medicine, Omicron, EU, Technology transfer, Clinical trial, International, Vaccination, The Post-Pandemic World Order, SARS-CoV-2, DPT vaccine, COVID-19, G&A, Diphtheria, Research, EV71, Respiratory syncytial virus, Influenza, CDMO, COVID-19 vaccine, RSV, International Financial Reporting Standards, Tetanus, Growth, Ageing, CpG, Immunodeficiency, Commercial, Health, Cross-promotion, Pharmaceutical industry, Cryptocurrency, Clover

SHANGHAI, China, March 29, 2023 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced corporate updates and financial results for the year ended December 31, 2022.

Key Points: 
  • (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced corporate updates and financial results for the year ended December 31, 2022.
  • Comprehensive Global Vaccine Development: Clinical trial results released and published in 2022 consistently demonstrated that SCB-2019 elicited broad cross-neutralization across variants.
  • Notably, in January 2022, Clover published the final efficacy results from its global Phase 2/3 study of SCB-2019 in The Lancet.
  • Clover also announced positive data from its Phase 3 study evaluating SCB-2019 as a heterologous COVID-19 booster vaccine.

Vaxart Provides Business Update and Full Year 2022 Financial Results

Retrieved on: 
Wednesday, March 15, 2023
Conference, AJPM, CFO, Workforce, SVB, Silicon Valley Bank, Webcast, Vaxart, Risk, SAN, PLOS, Gastroenteritis, Biotechnology, Antibody, SARS-CoV-2, Recollections of Full Years, Vaccination, Initiate, COVID-19, Research, MERS-related coronavirus, SCB-2019, Bill & Melinda Gates Foundation, Swine acute diarrhea syndrome coronavirus, Data, Breast milk, Bill, Clinical trial, Omicron, Conference call, Vaccine, Cryptocurrency, Pharmaceutical industry, Norovirus, Laninamivir

SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the full year 2022, during which Vaxart announced it is prioritizing development of the Company’s bivalent norovirus candidate.

Key Points: 
  • ET
    SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the full year 2022, during which Vaxart announced it is prioritizing development of the Company’s bivalent norovirus candidate.
  • In December 2022, Vaxart announced it will commence a new study of Vaxart’s oral norovirus vaccine candidate focused on protecting breastfeeding mothers and their infants.
  • Vaxart reported a net loss of $107.8 million for the full year 2022, compared to $70.5 million for the full year 2021.
  • The Vaxart senior management team will host a conference call to discuss the business update and financial results for the full year 2022 today, beginning at 4:30 p.m.

Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023

Retrieved on: 
Monday, January 16, 2023
Hospital, World Health Organization, Foot, Severe acute respiratory syndrome coronavirus 2, Pediatrics, SCB-2019, Commercial, COVID-19 vaccine, Oral and maxillofacial pathology, EUA, Death, Vaccination, Environment, Health, Research, Whooping cough, EMA, GMP, Development, WHO, Diphtheria, CAS-1, European Medicines Agency, RSV, Co-promotion, G&A, COVID-19, CpG, Safety, Respiratory syncytial virus, Vaccine, RMB, Omicron, Tetanus, EV71, DPT vaccine, Immunity, Pharmaceutical industry, Fine chemical, Risk management, Hand, Clover

SHANGHAI, China, Jan. 15, 2023 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today provided updates on the commercialization of SCB-2019 (CpG 1018/Alum) in China and strategic priorities in 2023.

Key Points: 
  • Commercial Launch Expected to Begin in Q1 2023: Clover has started commercial launch preparation activities in multiple key provinces and municipalities, based on Clover’s evaluation of market dynamics (including factors such as strategic fit, population size and competitive environment).
  • To date, Clover has received robust interest and demand based on the premium product profile of SCB-2019 and expects the commercial launch in these strategically prioritized areas to begin in Q1 2023.
  • At Least One In-Licensing Deal in H1 2023: At least one mid- to late-stage vaccine in-licensing deal announcement is expected in H1 2023.
  • SCB-2019: Concurrent with its commercial launch in China, Clover plans to conduct real-world effectiveness studies, with data potentially available in H2 2023.

Atreca Appoints Philippe Bishop, MD as Chief Medical Officer

Retrieved on: 
Monday, January 9, 2023
National Cancer Institute, Sanofi, University, Gilead Sciences, SCB-2019, National Institutes of Health, Regulation of tobacco by the U.S. Food and Drug Administration, Trial of the century, MD, University of Washington School of Medicine, Vaccine, Internal medicine, Food, Therapy, Genentech, Hematology-Oncology and Stem Cell Transplantation Research Center, SAN, Antibody, CMO, Hematology, Employment, Pharmaceutical industry

SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Philippe Bishop, MD, as Chief Medical Officer (CMO), effective immediately.

Key Points: 
  • SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Philippe Bishop, MD, as Chief Medical Officer (CMO), effective immediately.
  • Bishop is a tremendous addition to the Atreca team at an important time in the clinical development of ATRC-101.
  • As an accomplished executive and medical oncologist with extensive experience in cancer drug development, his leadership and expertise will be invaluable as we continue to advance ATRC-101, as well as our earlier stage programs,” said John Orwin, Chief Executive Officer of Atreca.
  • This award was granted as an inducement material to Dr. Bishop entering into employment with Atreca in accordance with Nasdaq Listing Rule 5635(c)(4).

Vaxart Names Phillip Lee as Chief Financial Officer

Retrieved on: 
Monday, December 19, 2022
Centerview, Missouri, Biotechnology, Debt monetization, CFO, Berkeley, Computer Sciences, Infection, Electrical engineering, University, SCB-2019, Pharmaceutical industry, Vaxart

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) announced today that it has appointed Phillip Lee as its Chief Financial Officer (CFO), effective immediately.

Key Points: 
  • Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more than $20 billion in transactions
    SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) announced today that it has appointed Phillip Lee as its Chief Financial Officer (CFO), effective immediately.
  • “We are excited to have a CFO with Phillip’s experience in corporate finance and strategy join our team,” said Andrei Floroiu, Vaxart’s Chief Executive Officer.
  • Most recently, he was CFO and Chief Operating Officer at Clover Biopharmaceuticals and prior to that held finance leadership positions at several biotechnology companies.
  • Mr. Lee earned dual bachelor’s degrees in Electrical Engineering and Computer Sciences and Business Administration from the University of California, Berkeley.

Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases

Retrieved on: 
Wednesday, November 30, 2022
Hospital, United Nations Development Programme, Risk, Hepatitis E, Therapy, International Vaccine Institute, Severe acute respiratory syndrome coronavirus 2, Shigella, European Medicines Agency, WHO, Infection, Omicron, United Nations, Aluminium, SCB-2019, National Medical Products Administration, Transcription-mediated amplification, PQ, Development, Public health, Salmonella, Adjuvant, Fever Dream, Chikungunya, Global health, Cholera, World Health Organization, CpG, HPV, 1018, Safety, IVI, Schistosomiasis, MD, Vaccination, 2020 European Medicines Agency cyberattack, Vaccine, Pharmaceutical industry, Clover, COVID-19, Trimer

SHANGHAI, China and SEOUL, Republic of Korea, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, and the International Vaccine Institute, an international nonprofit organization devoted to providing vaccines critical to global public health and based in Seoul, Korea, today announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

Key Points: 
  • Among the 134 household contacts of infected household members who had received SCB-2019, there was one case of COVID-19; among the 250 household contacts of infected household members who were not vaccinated, there were 12 cases.
  • There were no cases of symptomatic SARS-CoV-2 infection among household contacts who were partially or fully vaccinated and where the infected household member was vaccinated with SCB-2019.
  • This indicates that SCB-2019 vaccination reduced household transmission and that vaccinated household contacts also likely benefited from the protection provided by their own vaccination.
  • The study team was blinded to the assignment of SPECTRA participants to vaccine or placebo groups.

Clover Provides Update on 2022 Corporate Milestones

Retrieved on: 
Sunday, October 9, 2022
2020 European Medicines Agency cyberattack, Therapy, Efficiency, EMA, FleetBoston Financial, CBLA-FM, APA, LINK, Adolescence, European Medicines Agency, Safety, European Union response to the COVID-19 pandemic, NMPA, CAS-1, China Merchants Bank, Severe acute respiratory syndrome coronavirus 2, WHO, CDMO, CpG, World Health Organization, GLOBE, SCB-2019, Hospital, Development, Vaccine, National Medical Products Administration, Research, Aluminium, Technology, Ageing, Vaccination, World, 1018, Omicron, GMP, Profile, Business, US, Business development, Rabies, Forward-looking statement, COVID-19, Pharmaceutical industry, Trimer, Clover, EU

SHANGHAI, China, Oct. 09, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, today provided updates on its 2022 corporate milestones.

Key Points: 
  • (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, today provided updates on its 2022 corporate milestones.
  • Clover is poised to become a unique, integrated vaccine-focused company with established China and global R&D, manufacturing and commercialization capabilities.
  • The rolling submission to the China NMPA is expected to be completed in Q4 2022.
  • Clover completed the production-related technology transfer activities for SCB-2019 at the CDMO site in Q3 2022 and expects to complete submissions to the EMA and the WHO in Q4 2022.

Clover’s COVID-19 Vaccine Candidate Receives European Union GMP Certificate

Retrieved on: 
Tuesday, September 20, 2022
Aluminium, Therapy, Safety, SCB-2019, COVID-19, 1018, European Medicines Agency, World, World Health Organization, Severe acute respiratory syndrome coronavirus 2, National Medical Products Administration, EU, Forward-looking statement, Vaccine, CDMO, WHO, GLOBE, NMPA, CpG, GMP, EMA, Pharmaceutical industry, Clover, Trimer

(Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, today announced that Clovers contract development and manufacturing organization (CDMO) has received a European Union Good Manufacturing Practice (EU GMP) certificate for the production of Clovers lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum).

Key Points: 
  • (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, today announced that Clovers contract development and manufacturing organization (CDMO) has received a European Union Good Manufacturing Practice (EU GMP) certificate for the production of Clovers lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum).
  • The EU GMP certificate is in connection with Clovers regulatory submission to the European Medicines Agency (EMA) and follows a successful inspection of the CDMO site by the Ireland Health Products Regulatory Authority.
  • Obtaining the EU GMP certificate for SCB-2019 is a major milestone in our efforts to bring our premier COVID-19 vaccine candidate to global markets and a testament to the significant progress our team has made towards commercial readiness, said Joshua Liang, Chief Executive Officer and Executive Director of Clover.
  • Clover created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavaxs (Nasdaq: DVAX) CpG 1018 advanced adjuvant and aluminum hydroxide (alum).